In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:Clinical role of Ki-67 testingCore biopsies for identifying potential benefit with neoadjuvant endocrine therapyCombining CDK4/6 inhibition with tamoxifenPresenters:Javier Cortes, MD, PhDHead, Breast Cancer ProgramIOB Institute of OncologyMadrid and Barcelona, SpainStephen R. D. Johnston, MA, FRCP, PhDProfessor of Breast Cancer MedicineBreast UnitDepartment of MedicineRoyal Marsden HospitalLondon, United KingdomSara Tolaney, MD, MPHAssistant Professor of MedicineHarvard Medical SchoolAssociate DirectorSusan F Smith Center for Women’s CancerDirector of Clinical Trials, Breast Oncology Director of Breast Immunotherapy Clinical ResearchSenior PhysicianBreast Oncology ProgramDana-Farber Cancer InstituteBoston, Massachusetts, USAContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including downloadable slides and associated Podcast Pearls PDF:https://bit.ly/37tfvtj

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related